



Biotech Daily

Wednesday November 6, 2019

Daily news on ASX-listed biotechnology companies

- * **ASX, BIOTECH DOWN: ONCOSIL UP 17%; LBT, PHARMAXIS DOWN 7%**
- * **CELLMID SHARE PLAN RAISES \$1m; TOTAL \$2.5m**
- * **ACRUX RECEIVES FURTHER \$1.5m FEDERAL R&D TAX INCENTIVE**
- * **OVENTUS RECEIVES \$828k FEDERAL R&D TAX INCENTIVE**
- * **CELLMID, API TO SELL ÉVOLIS AT PRICELINE PHARMACIES**
- * **MICRO-X: 'CAPITAL MANAGEMENT, RAISING' HALT TO SUSPENSION**
- * **EISAI TAKES 7.2% OF COGSTATE**
- * **SICO INCREASED, DILUTED TO 7.7% IN PALLA, IN 2017**
- * **ELLEX TO LOSE DIRECTOR GIUSEPPE CANALA**
- * **NOXOPHARM APPOINTS ALEXANDER HUNTER CCO**

MARKET REPORT

The Australian stock market fell 0.55 percent on Wednesday November 6, 2019, with the ASX200 down 36.9 points to 6,660.2 points. Fifteen of the Biotech Daily Top 40 stocks were up, 19 fell, five traded unchanged and one was untraded. All three Big Caps fell.

Oncosil was the best for the second day in a row, up 2.5 cents or 16.7 percent to 17.5 cents with 6.1 million shares traded. Amplia and Immutep climbed more than five percent; Alterity, Antisense, Dimerix and Prescient improved more than four percent; Resonance was up 3.85 percent; Starpharma rose 2.5 percent; Cyclopharm and Proteomics were up more than one percent; with Mesoblast, Next Science, Paradigm and Volpara up by less than one percent.

LBT and Pharmaxis led the falls, LBT for the second day in a row, both down 1.5 cents or 7.3 percent to 19 cents, with 2.9 million and 27,949 shares traded, respectively. Clinuvel and Impedimed lost more than six percent; Patrys was down five percent; Imugene and Pro Medicus fell more than four percent; Orthocell and Resmed were down more than three percent; Compumedics, Kazia, Opthea, Osprey and Polynovo shed more than two percent; Cochlear, Cynata and Genetic Signatures were down more than one percent; with Avita, CSL, Medical Developments, Nanosonics and Telix down by less than one percent.

CELLMID

Cellmid says its share purchase plan at 20 cents a share has raised \$1,044,000 of an expected \$500,000.

In October, Cellmid said it planned to raise \$500,000 in a share plan, following a placement that raised \$1.5 million (BD: Oct 14, 2019).

Today, the company said the \$2.5 million would be used to drive growth in the consumer health business, including recent partnerships with Douglas GmbH, Habesul and the Australian Shopping Network.

Cellmid was up half a cent or 2.2 percent to 23 cents.

ACRUX

Acrux says it has received \$1,513,637 from the Australian Tax Office under the Federal Government Research and Development Tax Incentive program.

Acrux said the incentive was for wholly-owned subsidiary Acrux Pharma Pty Ltd for the year to June 30, 2019.

Last month, the company said its subsidiary Acrux Commercial had received \$501,605 under the Research and Development Tax Incentive program (BD: Oct 24, 2019).

Acrux fell half a cent or 2.1 percent to 23.5 cents.

OVENTUS MEDICAL

Oventus says it has received \$828,000 from the Australian Tax Office under the Federal Government Research and Development Tax Incentive program.

Oventus said the funds were for research activities for the year to June 30, 2019.

Oventus was up half a cent or one percent to 49 cents.

CELLMID

Cellmid says wholly-owned subsidiary Advangen International will sell its Évolis hair loss products in about 400 Priceline Pharmacy shops in Australia.

Cellmid said it had a trading agreement with Australian Pharmaceutical Industries, which said it owned Priceline, and that products were expected to be available in the pharmacies from November 2019.

MICRO-X

Micro-X says it has requested a voluntary suspension to follow its November 4, 2019 capital management review and capital raising trading halt (BD: Nov 4, 2019).

Micro-X said it expected the suspension to last until November 11, 2019 or on the release of an earlier announcement.

Micro-X last traded at 25 cents.

COGSTATE

Eisai says it has become a substantial shareholder in Cogstate with 11,738,243 shares or 7.16 percent of the company.

The Toyko-based Eisai said it acquired the shares between September 2 and November 1, 2019, for \$3,006,569 or an average of 25.6 cents a share.

Cogstate was unchanged at 35 cents.

PALLA PHARMA

Sico Holdings says that in 2017 it increased and was diluted in Palla, from 6,285,665 shares (12.22%) to 8,361,889 shares (7.74%).

In the first of two separate substantial shareholder notices, the Sydney-based Sico said that it bought 1,257,134 shares on April 11, 2017 for \$2,765,695 or \$2.20 a share, but was diluted from 12.22 percent to 10.4 percent of the company.

In the second shareholder notice, Sico said it bought 819,090 shares on April 20, 2017 for \$1,801,988 or \$2.20 a share, but was diluted from 10.35 percent to 7.74 percent of the company.

Palla fell 2.5 cents or three percent to 80.5 cents.

ELLEX MEDICAL LASERS

Ellex says former chairman Giuseppe Canala will retire as a non-executive director, effective from November 27, 2019.

Ellex said Mr Canala was a co-founder of Ellex and been its director of engineering, operations manager, managing director, company secretary and chairman.

Ellex chairman Victor Previn thanked Mr Canala for his “many years of service and the material contribution he has made as a director”.

“His extensive knowledge and experience in management, strategy, finance and corporate governance has been a valuable asset to the board,” Mr Previn said.

“I sincerely appreciate his wisdom and dedication and certainly wish him all the very best in his retirement,” Mr Previn said.

Ellex was unchanged at 60 cents.

NOXOPHARM

Noxopharm says it has appointed Alexander Hunter as its chief commercial officer.

Noxopharm said Mr Hunter had 15 years of experience in corporate finance, capital raising, mergers and acquisitions and growth company strategy, and was previously the chief financial officer of an ASX listed energy company.

The company said Mr Hunter was employed by Drillsearch Energy and was the chief financial officer of an unnamed energy company, and worked for advisory firm RFC Ambrian.

Noxopharm said that Me Hunter had worked for 10 years in project management for engineering and construction projects and corporate change management roles.

Noxopharm said Mr Hunter held a Bachelor of Engineering from the Armadale, New South Wales-based University of New England and a Master of Business Administration from the Los Angeles-based University of Southern California, as well as postgraduate qualifications in corporate finance and business law.

Noxopharm fell two cents or five percent to 38 cents.